Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-20T13:29:06.323Z Has data issue: false hasContentIssue false

Chapter 23 - Contraception in Women with Metabolic Conditions

from Section 2A - Sexual and Reproductive Healthcare: Contraception

Published online by Cambridge University Press:  16 January 2024

By
Angelo Cagnacci ,
Anna Biasioli ,
Claudia Massarotti ,
Laura Gabbi  and
Anjeza Xholli
Edited by
Johannes Bitzer  and
Tahir A. Mahmood
Johannes Bitzer
Affiliation:
University Women's Hospital, Basel
Tahir A. Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Get access

Summary

Diabetes and known dyslipidemia represent the main metabolic risk factors for cardiovascular disease [1, 2]. No contraceptive method has a clear contraindication in the presence of a single metabolic disease. Yet limitations, particularly to hormonal contraceptive methods, may apply when diseases develop that are associated with such methods of contraception or with additional cardiovascular risk factors [3, 4]. No contraindication applies to natural methods, barrier and interceptive contraception, or sterilization [3, 4]. Presence of a metabolic disease may require personalization of hormonal contraception, in particular combined hormonal contraceptives (CHCs) and systemic progestin-only contraceptives (POCs). In order to understand how hormonal contraception can be used in women with metabolic disease, it is useful to understand how exogenous hormones influence glucose and lipid metabolism.

Type
Chapter
Information
Textbook of Contraception, Sexual and Reproductive Health , pp. 159 - 164
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Yusuf, S, Hawken, S, Ounpuu, S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004;364(9438):937–52.CrossRefGoogle ScholarPubMed
O’Donnell, MJ, Xavier, D, Liu, L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet. 2010;376(9735):112–23.Google ScholarPubMed
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015.Google Scholar
Faculty of Sexual and Reproductive Healthcare. UK medical eligibility use. UKMEK 2016 (amended September 2019).Google Scholar
Cagnacci, A, Tuveri, F, Cirillo, R et al. The effect of transdermal 17-beta-estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. Maturitas. 1997;28:163–7.CrossRefGoogle Scholar
Lindheim, SR, Presser, SC, Ditkoff, EC et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril. 1993;60:664–7.CrossRefGoogle ScholarPubMed
De Pirro, R, Fusco, A, Bertoli, A, Greco, AV, Lauro, R. Insulin receptors during the menstrual cycle in normal women. J Clin Endocrinol Metab. 1978;47:1387–9.Google ScholarPubMed
Kojima, T, Lindheim, SR, Duffy, DM et al. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives. Am J Obstet Gynecol. 1993;169:1540–54.CrossRefGoogle ScholarPubMed
Sitruk-Ware, R, Nath, A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13–24.CrossRefGoogle ScholarPubMed
Cagnacci, A, Ferrari, S, Tirelli, A, Zanin, R, Volpe, A. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: A prospective randomized study. Contraception. 2009;80:34–9.CrossRefGoogle ScholarPubMed
Junge, W, Mellinger, U, Parke, S, Serrani, M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: A randomized, open-label, single-centre study. Clin Drug Investig. 2011;31:573–84.CrossRefGoogle ScholarPubMed
Ågren, UM, Anttila, M, Mäenpää-Liukko, K et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16:444–57.Google ScholarPubMed
Grandi, G, Piacenti, I, Volpe, A, Cagnacci, A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol. 2014;30:676–80.CrossRefGoogle ScholarPubMed
Waine, HFE. Metabolic effects of Enovid in rheumatoid patients. Arthritis Rheum. 1963;6:796.Google Scholar
Godsland, I, Walton, C, Felton, C, Proudler, A. Insulin resistance, secretion and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1991;74:64–70.Google Scholar
Cagnacci, A. Hormonal contraception: Venous and arterial disease. EJCRHC. 2017;22:191–9.Google ScholarPubMed
Corbould, A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol. 2007;192:585–94.CrossRefGoogle ScholarPubMed
National Institute for Health and Clinical Excellence. Management of diabetes from preconception to the postnatal period: Summary of NICE guidance. BMJ. 2008;336:714–17.Google Scholar
Napoli, A, Colatrella, A, Botta, R et al. Contraception in diabetic women: An Italian study. Diabetes Res Clin Pract. 2005;67:267–72.CrossRefGoogle ScholarPubMed
Cagnacci, A, Ferrari, S, Tirelli, A, Zanin, R, Volpe, A. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception. 2009;79:111–16.CrossRefGoogle ScholarPubMed
Monster, TB, Janssen, WM, De Jong, PE, De Jong–Van den Berg, LT. Prevention of renal and vascular end stage disease study group: Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med. 2001;161:2000–5.CrossRefGoogle Scholar
Dinger, J, Mohner, S, Heinemann, K. Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study. Front Women’s Health. 2020;5:1–8.CrossRefGoogle Scholar
Kivelä, A, Ruuskanen, M, Agren, U, Dieben, T. The effects of two progestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care. 2001;6:71–677.CrossRefGoogle ScholarPubMed
Benagiano, G, Primiero, FM. Seventy-five microgram desogestrel mini pill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci. 2003;997:163–73.CrossRefGoogle Scholar
Grandi, G, Cagnacci, A, Volpe, A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2013;10:1–10.CrossRefGoogle ScholarPubMed
Biswas, A, Viegas, OA, Coeling Bennink, HJ, Korver, T, Ratnam, SS. Implanon® contraceptive implants: Effects on carbohydrate metabolism. Contraception. 2001;63:137–41.CrossRefGoogle ScholarPubMed
Cagnacci, A, Tirelli, A, Cannoletta, M, Pirillo, D, Volpe, A. Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. Contraception. 2005;72:443–6.CrossRefGoogle ScholarPubMed
Vicente, L, Mendonça, D, Dingle, M, Duarte, R, Boavida, JM. Etonogestrel implant in women with diabetes mellitus. Eur J Contracept Reprod Health Care. 2008;13:387–95.CrossRefGoogle ScholarPubMed
Rosenfield, RL, Ehrmann, DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37:467–520.CrossRefGoogle ScholarPubMed
Randeva, HS, Tan, BK, Weickert, MO et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012;33:812–41.CrossRefGoogle ScholarPubMed
Dokras, A. Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome: Risks versus benefits. Fertil Steril. 2016;106:1572–9.CrossRefGoogle ScholarPubMed
De Medeiros, SF. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2017;15:93.CrossRefGoogle ScholarPubMed
Cagnacci, A, Paoletti, AM, Arangino, S, Melis, GB, Volpe, A. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Hum Reprod. 1999;14:893–7.CrossRefGoogle ScholarPubMed
Dahlgren, E, Landin, K, Krotkiewski, M, Holm, G, Janson, PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1998;13:2706–11.CrossRefGoogle ScholarPubMed
Moghetti, P. Insulin resistance and polycystic ovary syndrome. Curr Pharm Des. 2016;22:5526–34.CrossRefGoogle ScholarPubMed
Van der Mooren, MJ, Klipping, C, Van Aken, B et al. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999;4(Suppl 2):27–35.CrossRefGoogle ScholarPubMed
Lüdicke, F, Gaspard, UJ, Demeyer, F, Scheen, A, Lefebvre, P. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception. 2002;66:411–15.CrossRefGoogle ScholarPubMed
De Medeiros, SF. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2017;15:93.CrossRefGoogle ScholarPubMed
Amiri, M, Ramezani Tehrani, F, Nahidi, F et al. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. Metabolism. 2017;73:22–35.CrossRefGoogle ScholarPubMed
De Leo, V, Fruzzetti, F, Musacchio, MC et al. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception. 2013;88:364–8.CrossRefGoogle ScholarPubMed
Cagnacci, A, Paoletti, AM, Renzi, A et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab. 2003;88:3621–5.CrossRefGoogle ScholarPubMed
Oger, E. Incidence of venous thromboembolism: A community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657–60.Google Scholar
Fruzzetti, F, Cagnacci, A. Venous thrombosis and hormonal contraception: What’s new with estradiol-based hormonal contraceptives? Open Access J Contracept. 2018;9:75–9.CrossRefGoogle ScholarPubMed
Klipping, C, Duijkers, I, Mawet, M et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103:213–21.CrossRefGoogle ScholarPubMed
Salazar, MR, Carbajal, HA, Espeche, WG et al. Identifying cardiovascular disease risk and outcome: Use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. J Intern Med. 2013;273:595–601.CrossRefGoogle ScholarPubMed
Knopp, RH, Zhu, X, Bonet, B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis. 1994;110(Suppl):S83–S91.CrossRefGoogle ScholarPubMed
Sitruk-Ware, R, Plu-Bureau, G, Menard, J et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab. 2007;92:2074–9.CrossRefGoogle Scholar
La Rosa, JC. The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol. 1988;158:1821–9.CrossRefGoogle ScholarPubMed
Upton, V. Lipids, cardiovascular disease, and oral contraceptives: A practical perspective. Fertil Steril. 1990;53:1–12.Google ScholarPubMed
Godsland, IF, Crook, D, Simpson, R et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323:1375–81.CrossRefGoogle ScholarPubMed
Barkfeldt, J, Virkkunen, A, Dieben, T. The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism. Contraception. 2001;64:295–9.CrossRefGoogle Scholar
Suherman, SK, Affandi, B KT. The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception. 1999;60:281–7.CrossRefGoogle ScholarPubMed
Mascarenhas, L, Van Beek, A, Bennink, HC NJ. Twenty-four month comparison of apolipoproteins A-1, A-II and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. Contraception. 1998;58:215–19.CrossRefGoogle Scholar
Dragoman, M, Curtis, KM, Gaffield, ME. Combined hormonal contraceptive use among women with known dyslipidemias: A systematic review of critical safety outcomes. Contraception. 2016;94:280–7.CrossRefGoogle ScholarPubMed
Ng, YW, Liang, S, Singh, K. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism: A randomized comparative study. Contraception. 2009;79:24–8.CrossRefGoogle ScholarPubMed
Zueff, LFN, Melo, AS de, Vieira, CS, Martins, WP, Ferriani, RA. Cardiovascular risk markers among obese women using the levonorgestrel-releasing intrauterine system: A randomised controlled trial. Obes Res Clin Pract. 2017;11:687–93.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×